Premium Banking

Showing 998 articles
Business

ING Groep Raises Income Outlook on Strong Fee Growth, Fuels Investor Debate

ING Groep's latest financial results reveal a strategic pivot gaining traction, with fee income now accounting for a fifth of total revenue. The bank has upgraded its income guidance for 2026 and 2027, alongside a robust shareholder return policy, prompting analysts to reassess its growth narrative in a challenging European banking landscape.

Business

AbCellera Biologics: A Valuation Crossroads After Volatile Returns

Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.